Oral composition of palbociclib

The oral composition of palbociclib with ascorbic acid addresses absorption and stability issues by stabilizing pH variations in the gastrointestinal tract, ensuring consistent absorption and storage stability, and maintaining stable blood concentrations.

WO2024242504A1PCT designated stage expired Publication Date: 2024-11-28SAMYANG HLDG CORP
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/007097
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-25
Filing Date
2024-05-24
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Oral administration of palbociclib is affected by pH variations in the gastrointestinal tract, leading to inconsistent absorption and stability issues, particularly when taken with or without food, and is exacerbated by the use of proton pump inhibitors or H2 receptor antagonists.

Method used

An oral composition of palbociclib incorporating ascorbic acid and a pharmaceutically acceptable carrier or additive, with ascorbic acid content exceeding 0.25 parts by weight per part of palbociclib, which stabilizes absorption and storage stability by compensating for pH changes and improving dissolution characteristics.

Benefits of technology

The composition ensures consistent drug absorption regardless of food intake and maintains stable blood concentrations, while exhibiting excellent storage stability and pharmacokinetic characteristics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024007097_28112024_PF_FP_ABST
    Figure KR2024007097_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to an oral composition of palbociclib or a pharmaceutically acceptable salt thereof useful for the treatment of advanced or metastatic breast cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Oral composition of palbociclib

[0001] The present invention relates to an oral composition of palbociclib or a pharmaceutically acceptable salt thereof, which is useful for treating advanced or metastatic breast cancer.

[0002] Palbociclib is a compound with the following chemical structure and is a potent and selective inhibitor of CDK4 and CDK6.

[0003] [Palbociclip]

[0004]

[0005] Palbociclib is indicated for the treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor as first-line endocrine therapy in postmenopausal women or in combination with fulvestrant in women whose disease has progressed following endocrine therapy. Palbociclib is marketed by Pfizer under the brand name IBRANCE (registered trademark). ® Capsules must be taken with food as deviations may occur when taken on an empty stomach.

[0006] Orally administered drugs can be affected by pH changes as they pass through the gastrointestinal tract, as the pH of the gastrointestinal tract varies across different sites. For example, the pH of the stomach ranges from 1 to 3.5, while that of the small intestine ranges from 4.5 to 8, a significant difference. Furthermore, even within the same patient, the pH environment encountered by an orally administered drug can vary depending on the patient's condition, whether they have consumed food, and whether or not they are taking medications such as proton pump inhibitors (PPIs) or H2 receptor antagonists. Furthermore, the gastrointestinal retention time of drugs is generally longer in the presence of food than in the fasted state. Drugs with pH-dependent solubility, in particular, can precipitate out of solution as they pass through the gastrointestinal tract, leading to inter- and intra-patient variability in absorption.

[0007] The present invention aims to provide an oral formulation of palbociclib that has no difference in drug absorption regardless of food intake by compensating for changes in the pH of the gastrointestinal tract upon oral administration, and further has desirable storage stability and dissolution and pharmacokinetic characteristics.

[0008] One aspect of the present invention provides an oral composition comprising palbociclib as an active ingredient; ascorbic acid; and a pharmaceutically acceptable carrier or additive.

[0009] According to one specific example, the content of ascorbic acid in the oral composition of the present invention exceeds 0.25 parts by weight based on 1 part by weight of palbociclib.

[0010] Another aspect of the present invention provides a method for preparing an oral composition, comprising the step of preparing a mixture comprising palbociclib as an active ingredient, ascorbic acid, and a pharmaceutically acceptable carrier or additive.

[0011] According to one specific example, the content of ascorbic acid in the prepared mixture exceeds 0.25 parts by weight based on 1 part by weight of palbociclib.

[0012] The oral composition of palbociclib provided according to the present invention can stably maintain the blood concentration of the drug without any difference in drug absorption regardless of food intake, and further exhibits excellent storage stability.

[0013] Figure 1 is a graph showing the results of a dissolution test performed in Test Example 6 of the present invention.

[0014] Definition of terms

[0015] Unless explicitly stated otherwise, certain terms used throughout this specification are defined as follows.

[0016] Unless otherwise specified throughout this specification, the terms “include” or “comprising” refer to the inclusion of a certain component (or component) without limitation, and are not to be construed as excluding the addition of other components (or components).

[0017] The oral composition of palbociclib according to the present invention comprises palbociclib as an active ingredient.

[0018] In the present invention, the "palbociclib" may be a free base of palbociclib (a base drug without a separate salt), a pharmaceutically acceptable salt thereof, an isomer thereof, or a mixture thereof. In addition, in each case, it may form various hydrates, and in each case, various crystalline forms. For example, it may be various hydrates such as anhydrous palbociclib, hemihydrate, monohydrate, dihydrate, trihydrate, or various solvates, or a mixture thereof.

[0019] The oral composition of palbociclib according to the present invention also comprises ascorbic acid.

[0020] Ascorbic acid, also known as vitamin C, has the chemical structure of L-ascorbic acid:

[0021]

[0022] In the present invention, the ascorbic acid, when the palbociclib tablet of the present invention is administered orally, counteracts the change in pH of the gastrointestinal tract, thereby ensuring that there is no difference in drug absorption regardless of food intake, and further improves the storage stability of the palbociclib tablet.

[0023] In one specific example, the oral composition of the present invention may contain ascorbic acid in an amount greater than 0.25 parts by weight based on 1 part by weight of palbociclib. If the content of ascorbic acid in the oral composition of the present invention is 0.25 parts by weight or less based on 1 part by weight of palbociclib, the dissolution rate (in water) of palbociclib from the tablet may be reduced.

[0024] More specifically, the ascorbic acid content in the oral composition of the present invention may be 0.26 parts by weight or more, 0.3 parts by weight or more, 0.35 parts by weight or more, 0.4 parts by weight or more, or 0.45 parts by weight or more, based on 1 part by weight of palbociclib, but is not limited thereto.

[0025] There is no particular limitation on the upper limit of the ascorbic acid content in the oral composition of the present invention, but if the ascorbic acid content in the composition is excessively high, the physical properties and storage stability of the composition may be affected. In one specific example, the ascorbic acid content in the oral composition of the present invention may be 5 parts by weight or less, 4.5 parts by weight or less, 4 parts by weight or less, 3.5 parts by weight or less, 3 parts by weight or less, 2.5 parts by weight or less, 2 parts by weight or less, 1.5 parts by weight or less, or 1 part by weight or less, based on 1 part by weight of palbociclib, but is not limited thereto.

[0026] In one embodiment, the oral composition of the present invention may further comprise an additional water-soluble acid other than ascorbic acid. In one embodiment, the additional water-soluble acid may be selected from the group consisting of, but is not limited to, citric acid, malic acid, tartaric acid, fumaric acid, maleic acid, succinic acid, aspartic acid, lactic acid, acetic acid, glutamic acid, sorbic acid, phosphoric acid, hydrochloric acid, and mixtures thereof.

[0027] The oral composition of palbociclib according to the present invention also comprises a pharmaceutically acceptable carrier or additive.

[0028] In one specific embodiment, the pharmaceutically acceptable carrier or additive may be one or more selected from a diluent, a lubricant, a disintegrant, and a binder.

[0029] In one embodiment, the oral composition of the present invention may include a diluent.

[0030] In one embodiment, the diluent may be selected from the group consisting of sugar, sugar alcohol, cellulose, starch, inorganic salts and mixtures thereof, and more specifically, from the group consisting of lactose (anhydrous or hydrated, for example, monohydrate), cellulose powder, microcrystalline cellulose (MCC), silicified microcrystalline cellulose, starch, pregelatinized starch, calcium carbonate, cyclodextrin, calcium sulfate, calcium silicate, magnesium carbonate, dicalcium phosphate, tricalcium phosphate, magnesium trisilicate, potassium chloride, sodium chloride, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, mannitol, maltitol, sorbitol, xylitol, lactose, dextrose, maltose, sucrose, glucose, fructose, maltodextrin, dextrates, dextrins and mixtures thereof. May be selected, but is not limited to:

[0031] In one specific example, the diluent may also function as a binder.

[0032] In one specific example, when a diluent is used in the oral composition of the present invention, the amount used may be 0.5 parts by weight or more, 1 part by weight or more, or 1.5 parts by weight or more, based on 1 part by weight of palbociclib, and may also be 400 parts by weight or less, 200 parts by weight or less, 100 parts by weight or less, 50 parts by weight or less, or 20 parts by weight or less, but is not limited thereto.

[0033] In one embodiment, the oral composition of the present invention may include a lubricant.

[0034] In one embodiment, the lubricant may be selected from the group consisting of soluble lubricants, insoluble lubricants, and mixtures thereof, and more specifically, may be selected from the group consisting of magnesium stearate, fumaric acid, stearic acid, calcium stearate, sodium stearyl fumarate, sucrose fatty acid esters, starch, talc, colloidal silicon dioxide, magnesium oxide, magnesium carbonate, glyceryl monostearate, silicon dioxide, calcium silicate, magnesium silicate, hydrogenated vegetable oil, light liquid paraffin, polyethylene glycol, sodium lauryl sulfate, magnesium lauryl sulfate, sodium benzoate, polyoxyethylene monostearate, glyceryl triacetate, sucrose monolaurate, and mixtures thereof, but is not limited thereto.

[0035] In one specific example, when a lubricant is used in the oral composition of the present invention, the amount used may be 0.001 parts by weight or more, 0.005 parts by weight or more, or 0.01 parts by weight or more, and may also be 10 parts by weight or less, 5 parts by weight or less, or 1 part by weight or less, based on 1 part by weight of palbociclib, but is not limited thereto.

[0036] In one embodiment, the oral composition of the present invention may include a disintegrant.

[0037] In one specific example, the disintegrant may be selected from the group consisting of, but is not limited to, croscarmellose sodium (CrosCMC-Na), carboxymethylcellulose, crospovidone (cross-linked polyvinylpyrrolidone), low-substituted hydroxypropylcellulose (L-HPC), starch, pregelatinized starch, sodium carboxymethyl starch, sodium starch glycolate, partially hydrolyzed starch, and mixtures thereof.

[0038] In one specific example, when a disintegrant is used in the oral composition of the present invention, the amount used may be 0.001 parts by weight or more, 0.005 parts by weight or more, or 0.01 parts by weight or more, and may also be 10 parts by weight or less, 5 parts by weight or less, or 1 part by weight or less, based on 1 part by weight of palbociclib, but is not limited thereto.

[0039] In one embodiment, the oral composition of the present invention may comprise a binder.

[0040] In one specific embodiment, the binder may be selected from the group consisting of, but is not limited to, povidone, polyvinyl pyrrolidone, polyvinyl alcohol, carbopol, hydroxypropyl methylcellulose, hydroxypropyl cellulose (HPC), low-substituted hydroxypropyl cellulose (HPC-L), carboxymethyl cellulose, carboxymethyl cellulose sodium, hydroxyethyl cellulose, pullulan, carboxyvinyl polymer polyethylene glycol or derivatives thereof, and mixtures thereof.

[0041] In one specific example, when a binder is used in the oral composition of the present invention, the amount used may be 0.001 parts by weight or more, 0.005 parts by weight or more, or 0.01 parts by weight or more, and may also be 10 parts by weight or less, 5 parts by weight or less, or 1 part by weight or less, based on 1 part by weight of palbociclib, but is not limited thereto.

[0042] The oral composition of the present invention can be formulated into a variety of oral dosage forms. Examples of such oral dosage forms include, but are not limited to, tablets, capsules, powders, and liquids.

[0043] In one specific embodiment, the oral composition of the present invention may be a tablet.

[0044] In one specific embodiment, when the oral composition of the present invention is a tablet, it may further include a coating layer.

[0045] In one specific example, the coating agent forming the coating layer may be selected from the group consisting of polyvinylpyrrolidone, hydroxypropylmethylcellulose, carboxymethylcellulose and salts thereof, ethylcellulose, methylcellulose, hydroxyethylcellulose, ethylhydroxyethylcellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, polyvinyl alcohol, macrogol polyvinyl alcohol graft copolymer, polymers of acrylic acid and salts thereof, polymethacrylate, poly(butyl methacrylate, 2-dimethylaminoethyl methacrylate, methyl methacrylate) copolymer, vinylpyrrolidone-vinylacetate copolymer, gelatin, guar gum, partially hydrolyzed starch, alginate, xanthan and mixtures thereof.

[0046] In one specific example, when the oral composition of the present invention is a tablet and further comprises a coating layer, the content thereof may be 1 part by weight or more, 2 parts by weight or more, 3 parts by weight or more, 4 parts by weight or more, 5 parts by weight or more, or 6 parts by weight or more, and may also be 30 parts by weight or less, 25 parts by weight or less, 20 parts by weight or less, or 15 parts by weight or less, but is not limited thereto. If the coating layer content is less than the above range, the entire tablet may not be sufficiently coated, and conversely, if it is more than the above range, the dissolution rate may be delayed.

[0047] The purpose of coating is to improve the stability of the tablet and prevent drug loss. Therefore, a second coating may be applied after the first, if necessary, and the coating thickness can be selected appropriately. However, as mentioned above, the coating must not delay drug dissolution, so an appropriate range must be selected. The remaining components and methods required for coating can be appropriately selected by those skilled in the art.

[0048] According to another aspect of the present invention, a method for preparing an oral composition is provided, comprising the step of preparing a mixture comprising palbociclib as an active ingredient, ascorbic acid, and a pharmaceutically acceptable carrier or additive.

[0049] According to one specific example, ascorbic acid may be present in the prepared mixture in an amount exceeding 0.25 parts by weight based on 1 part by weight of palbociclib.

[0050] More specifically, the ascorbic acid content in the above-mentioned manufactured mixture may be 0.26 parts by weight or more, 0.3 parts by weight or more, 0.35 parts by weight or more, 0.4 parts by weight or more, or 0.45 parts by weight or more, based on 1 part by weight of palbociclib, but is not limited thereto.

[0051] In one specific example, when the oral composition of the present invention is a tablet, the method for preparing the oral composition may further include a step of compressing the prepared mixture into a tablet.

[0052] In one specific embodiment, the mixture to be prepared may further comprise a diluent, wherein the diluents usable herein are as described above.

[0053] In one specific embodiment, the mixture to be formed may further comprise a lubricant, wherein the lubricants usable herein are as described above.

[0054] In one specific embodiment, the mixture to be formed may further comprise a disintegrant, wherein the usable lubricants are as described above.

[0055] In one specific embodiment, the mixture to be formed may further comprise a binder, wherein the binders usable herein are as described above.

[0056] In one specific embodiment, the mixture to be formed may further comprise an additional water-soluble acid other than ascorbic acid, wherein the additional water-soluble acid usable herein is as described above.

[0057] In one specific example, when the oral composition of the present invention is a tablet, the method for producing the oral composition may additionally include a step of coating the surface of the tablet (uncoated tablet) obtained as a result of the tableting with a coating agent, and the coating agent that can be used here is as described above.

[0058] In one specific example, when the oral composition of the present invention is a tablet, it may be manufactured by mixing and granulating palbociclib as an active ingredient and an additive (e.g., at least one of a diluent, a lubricant, a disintegrant, and a binder), then adding ascorbic acid and an additional additive (e.g., at least one of a diluent, a lubricant, a disintegrant, and a binder) thereto, post-mixing, compressing the resulting mixture, and optionally coating the resulting tablet (uncoated tablet), but is not limited thereto.

[0059] The above granulation can be performed by dry granulation, wet granulation, etc.

[0060] In one specific example, when granulating using wet granulation, a binder solution is prepared, a diluent, etc. are added along with the drug, and the resulting mixture is mixed with the binder solution to form granules, which are then sieved and dried to obtain granules. Afterwards, the remaining ingredients are mixed through post-mixing and then compressed into tablets.

[0061] In one specific example, when granulating with dry granules, a mixture of the drug and a diluent, etc., is compressed using a roller compactor, etc., and then sieved, and then the remaining ingredients are mixed through post-mixing and then tableted.

[0062] Hereinafter, examples are presented to aid in understanding the present invention. However, the following examples are intended only to illustrate the present invention and are not intended to limit the present invention to these examples.

[0063] [Example]

[0064] Ingredients used

[0065] - Palbociclib

[0066] - Ascorbic acid

[0067] - Microcrystalline cellulose (MCC) (vivapur 102): diluent

[0068] - Colloidal silicon dioxide (Aerosil 200): lubricant

[0069] - Crospovidone (Kollidon CL): disintegrant

[0070] - Magnesium stearate (S-Mg): lubricant

[0071] Example 1

[0072] After granulation and post-mixing processes were performed using the ingredients in the amounts shown in Table 1 below, the resulting mixture was pressed into rectangular punches with a weight of 625 mg per tablet to prepare oral tablets.

[0073] Comparative Example 1

[0074] Oral tablets were prepared in the same manner as in Example 1, except that the same amount of fumaric acid was used instead of ascorbic acid.

[0075] Comparative Example 2

[0076] Oral tablets were prepared in the same manner as in Example 1, except that the same amount of lactic acid was used instead of ascorbic acid.

[0077] [Table 1]

[0078]

[0079]

[0080] Test Example 1: Dissolution Test

[0081] For each tablet manufactured in Example 1 and Comparative Examples 1 and 2, a dissolution test was conducted under the following conditions according to the delayed release dissolution method 2 (paddle method) of the USP monograph. The dissolution test was performed 3 hours after the start of the test, and the results are shown in Table 2 below.

[0082] <Dissolution Test Method>

[0083] Eluate: pH 5.5 sodium acetate buffer 500 mL

[0084] Rotation speed: 50 rpm

[0085] Temperature: 37℃

[0086] Analysis method: HPLC analysis method

[0087] [Table 2]

[0088]

[0089]

[0090] Test Example 2: Rat pharmacokinetic (PK) study

[0091] Ibrance, a commercially available drug, as a control group ® A nonclinical pharmacokinetic (PK) study was conducted on the tablets of Example 1 in rats. SD rats (male, 6 per group) were used as experimental animals, and the administered dose was 15 mg / kg po (using a sonde), which was dispersed in water (DW) and administered. Blood samples collected for each specimen were frozen and stored after plasma separation, and the concentration was analyzed using LC / MS / MS equipment to obtain blood concentrations over time. The AUC and Cmax were calculated from the data, and the results are summarized in Table 3 below.

[0092] [Table 3]

[0093]

[0094]

[0095] Test Example 3: Beagle pharmacokinetic (PK) test

[0096] Ibrance, a commercially available drug, as a control group ® A nonclinical pharmacokinetic (PK) study was conducted on the tablets of Example 1 in Beagle dogs. The experimental animals used were male Beagles (6 per group), and the administered dose was 1 tablet (125 mg Palbociclib) / head, administered orally with 20 ml of water (DW). Blood samples collected for each specimen were frozen and stored after plasma separation. The concentration was analyzed using LC / MS / MS equipment to obtain blood concentrations over time. The AUC and Cmax were calculated from the data, and the results are summarized in Table 4 below.

[0097]

[0098] [Table 4]

[0099]

[0100]

[0101] Test Example 4: Preliminary Acceleration Stability Test

[0102] Ibrance, a commercially available drug, as a control group ® Each tablet manufactured in Example 1 and Comparative Examples 1 to 2 was packaged in Al-Al and stored at 40°C and 75% RH (accelerated conditions) for 6 months. The content of flexible substances in the tablets was then checked, and the results are shown in Table 5 below.

[0103] [Table 5]

[0104]

[0105]

[0106] Test Example 5: Beagle Pharmacokinetic (PK) Study: Conditions of Concomitant Use with Proton Pump Inhibitors (PPIs)

[0107] Ibrance, a formulation that improves dietary impact ®Jeong is a product that maintains constant PK parameters regardless of the dosage regimen, such as whether or not meals are taken or whether PPIs are used concomitantly. As a control group, Ibrance, which is currently on the market, was used. ® A nonclinical pharmacokinetic (PK) study on the combination of PPI and the tablet of Example 1, which secured equivalence under the pre-meal single condition, was conducted in Beagle dogs. Beagle dogs (male, 5 per group) were used as experimental animals, and the administered dose was 1 tablet (125 mg Palbociclib) / head, administered orally with 20 ml of water (DW). Each control and test group was administered 1 mg / kg rabeprazole as a PPI intravenously 1 hour before oral tablet administration. Blood samples collected for each specimen were frozen and stored after plasma separation, and the concentration was analyzed using LC / MS / MS equipment to obtain blood concentrations over time. The AUC and Cmax were obtained from the data, and the results are summarized in Table 6 below.

[0108] [Table 6]

[0109]

[0110]

[0111] Test Example 6: Comparison of dissolution rates according to the ratio of palbociclib / ascorbic acid (in water)

[0112] After granulation and post-mixing processes were performed using the ingredients in the amounts shown in Table 7 below, the resulting mixture was compressed into tablets using a rectangular punch to prepare oral tablets of Comparative Example 3 and Example 2. The composition of the tablets of Example 1 is also shown in Table 7.

[0113] [Table 7]

[0114]

[0115]

[0116] Ibrance, a commercially available drug, as a control group ®For each tablet of Examples 1 and 2 and Comparative Example 3, a dissolution test was performed under the following conditions according to the delayed release dissolution method 2 (paddle method) of the USP monograph, and the results are shown in Figure 1.

[0117] <Dissolution Test Method>

[0118] Dissolution solution: 900 mL of water

[0119] Rotation speed: 50 rpm

[0120] Temperature: 37℃

[0121] Analysis method: HPLC analysis method

[0122] Meanwhile, after the dissolution test in the above water, the pH of the dissolution solution at the point where the final dissolution rate was reached was measured, and this is shown in Table 8 below along with the pH before dissolution.

[0123] [Table 8]

[0124]

Claims

1. As an oral composition, Palbociclib as the active ingredient; ascorbic acid; and containing a pharmaceutically acceptable carrier or excipient; Oral compositions 2. An oral composition according to claim 1, wherein the content of ascorbic acid in the composition exceeds 0.25 parts by weight based on 1 part by weight of palbociclib.

3. An oral composition further comprising an additional water-soluble acid other than ascorbic acid in the first paragraph.

4. An oral composition according to claim 3, wherein the additional water-soluble acid is selected from the group consisting of citric acid, malic acid, tartaric acid, fumaric acid, maleic acid, succinic acid, aspartic acid, lactic acid, acetic acid, glutamic acid, sorbic acid, phosphoric acid, hydrochloric acid and mixtures thereof.

5. An oral composition according to claim 1, wherein the pharmaceutically acceptable carrier or additive is at least one selected from a diluent, a lubricant, a disintegrant, and a binder.

6. An oral composition according to claim 5, wherein the diluent is selected from the group consisting of sugar, sugar alcohol, cellulose, starch, inorganic salts, and mixtures thereof.

7. An oral composition according to claim 5, wherein the lubricant is selected from the group consisting of magnesium stearate, fumaric acid, stearic acid, calcium stearate, sodium stearyl fumarate, sucrose fatty acid ester, starch, talc, colloidal silicon dioxide, magnesium oxide, magnesium carbonate, glyceryl monostearate, silicon dioxide, calcium silicate, magnesium silicate, hydrogenated vegetable oil, light liquid paraffin, polyethylene glycol, sodium lauryl sulfate, magnesium lauryl sulfate, sodium benzoate, polyoxyethylene monostearate, glyceryl triacetate, sucrose monolaurate, and mixtures thereof.

8. An oral composition according to claim 5, wherein the disintegrant is selected from the group consisting of croscarmellose sodium, carboxymethylcellulose, crospovidone, low-substituted hydroxypropylcellulose, starch, pregelatinized starch, sodium carboxymethyl starch, sodium starch glycolate, partially hydrolyzed starch, and mixtures thereof.

9. An oral composition according to claim 5, wherein the binder is selected from the group consisting of povidone, polyvinyl pyrrolidone, polyvinyl alcohol, carbopol, hydroxypropyl methylcellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose sodium, hydroxyethyl cellulose, pullulan, carboxyvinyl polymer polyethylene glycol or derivatives thereof, and mixtures thereof.

10. An oral composition according to any one of claims 1 to 9, further comprising a coating layer.

11. A method for preparing an oral composition, comprising the step of preparing a mixture comprising palbociclib as an active ingredient, ascorbic acid, and a pharmaceutically acceptable carrier or additive.

12. A method for producing an oral composition according to claim 11, wherein the content of ascorbic acid in the prepared mixture exceeds 0.25 parts by weight based on 1 part by weight of palbociclib.

Citation Information

Patent Citations

  • Chemical compounds

    KR1020160013198A

  • Composition for measuring of acetylcholinesteras activity and method for measuring of acetylcholinesterase activity using the same

    KR1020200095850A

  • Electric element assembly

    KR1020240116331A

  • Modified particles of palbociclib

    WO2016156070A1

  • Solid dosage forms of palbociclib

    WO2022029799A1